Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer

At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Explain best pr...

23 Dec 202041min

Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020) Presented by Leonard Gomella, MD and Joshua Lang, MD This...

20 Dec 202027min

Presented by Kelly Stratton, MD and Alicia Morgans, MD This educational activity is supported by independent educational grants from: AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc...

18 Dec 202034min

Case-Based Discussion: BCR and mHSPC and M0 CRPC Presented by Stephen Boorjian, MD and Michael Cookson, MD This educational activity is supported by independent educational grants from: AbbVie Aste...

15 Dec 202045min

At the conclusion of this activity, participants will be able to: 1. Identify the role of genetic testing in men with advanced, metastatic and CRPC. 2. State the criteria for genetic testing of prosta...

9 Dec 202028min

At the conclusion of this activity, participants will be able to: 1. Examine racial and geographic disparities in in prostate cancer and prostate cancer care. 2. Identify important causes for disparit...

2 Dec 202032min

At the conclusion of this activity, participants will be able to: 1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment. 2. Facilitate ...

25 Nov 202038min

At the conclusion of this activity, participants will be able to: 1. Review the evidence and outcomes on the treatment of M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced, Me...

18 Nov 202023min